ABSTRACT
Risks of third-trimester amniocentesis are considered minimal; however, only case
series have been reported. We performed a case-control study in which women undergoing
third-trimester amniocentesis were matched with controls undergoing antenatal testing
for similar indications to determine adverse outcomes associated with the procedure.
Cases undergoing amniocentesis at > 32 weeks for fetal lung maturity assessment followed
by antepartum testing with nonstress test and amniotic fluid index determination were
matched with controls undergoing only antepartum testing based on gestational age
at testing and maternal age. The main outcome variable was a composite occurrence
of obstetric complications within 48 hours of testing, including urgent delivery,
placental abruption, premature rupture of membranes (PROM), perinatal death, or Apgar
score at 5 minutes < 7. Statistical analysis included Fisher's exact test and Student
t-test, with p < 0.05 considered significant. A total of 167 matched pairs of patients fulfilled
the study criteria. Indications for both amniocentesis and antepartum testing, which
included diabetes, preterm labor, and cholestasis, were similar in the two groups.
As expected, gestational age at sampling/testing (36.4 ± 1.4 [mean ± standard deviation]
versus 36.6 ± 1.7 weeks; p = 0.2) and maternal age (31.4 ± 5.8 versus 31.5 ± 6.3 years; p = 0.9) were not different between cases and controls. The rate of the main outcome
variable within 48 hours of testing was 0 of 167 among cases and 1 of 167 among controls.
Amniocentesis in the third trimester is not associated with increased risk of urgent
delivery, placental abruption, PROM, Apgar score at 5 minutes < 7, or perinatal death
within 48 hours of the procedure.
KEYWORDS
Amniocentesis - pregnancy complications - pregnancy third trimester
REFERENCES
- 1
Stark C M, Smith R S, Lagrandeur R M, Batton D G, Lorenz R P.
Need for urgent delivery after third trimester amniocentesis.
Obstet Gynecol.
2000;
95
48-50
- 2
Gordon M C, Narula K, O'shaughnessy R, Barth Jr W H.
Complications of third-trimester amniocentesis using continuous ultrasound guidance.
Obstet Gynecol.
2002;
99
255-259
- 3 Sabbagha R, Salvino C. Report on third trimester amniocentesis at Prentice Women's
Hospital of Northwestern University Medical School, Chicago, Illinois. In: Antenatal
Diagnosis. NIH Consensus Statement. Bethesda, MD; National Institutes of Health 1979:
65-74
- 4 Young B K. Report of third trimester amniocentesis at New York University Medical
Center, New York, NY. In: Antenatal Diagnosis. NIH Consensus Statement. Bethesda,
MD; National Institutes of Health 1979: 65-74
- 5
Haeusler M C, Konstantiniuk P, Dorfer M, Weiss P A.
Amniotic fluid insulin testing in gestational diabetes: safety and acceptance of amniocentesis.
Am J Obstet Gynecol.
1998;
179
917-920
- 6
Yeast J D, Garite T J, Dorchester W.
The risks of amniocentesis in the management of premature rupture of membranes.
Am J Obstet Gynecol.
1984;
149
505-508
Jonathan G HodorD.O.
M.S., Department of Obstetrics and Gynecology
Division of Maternal-Fetal Medicine, 3800 Reservoir Road, N.W., 3PHC, Washington,
DC 20007